has decided to embark on the path of fine-tuning and developing rhNGF in its formulation for clinical use, at its own biotech facility in L’Aquila. and in Naples, where there are the laboratories of Drug Discovery and Technology Formulation, within a long-term collaboration with CNR. Italian excellence: the Dompé Hub in L’Aquila. Dompé has concentrated its manufacturing and research and development activities at its L’Aquila hub.

Author: Nikolar Maum
Country: Russian Federation
Language: English (Spanish)
Genre: Finance
Published (Last): 9 August 2006
Pages: 406
PDF File Size: 1.21 Mb
ePub File Size: 5.31 Mb
ISBN: 702-2-25893-164-7
Downloads: 39719
Price: Free* [*Free Regsitration Required]
Uploader: Vukus

It received European Union Approval in July, for the treatment of moderate to severe neurotrophic keratitis.

Click here to continue reading. Do you want to be redirected to the mobile version?

The aim is to convey all the metabolic energy of the bacterium with a solely reproductive aim. This unit also promotes networking for the development of highly-valued design platform partnerships.

The safety and efficacy of Oxervate, a topical eye drop containing cenegermin, was studied in a total of patients with neurotrophic keratitis in for,ulation, eight-week, randomized controlled multi-center, double-masked studies.

Accessing the website you have selected you will be subject to the terms of use of this last. The application of Smart Factory concepts in the pharma context, in fact, is accompanied by certain peculiarities linked to qualitative and regulatory aspects.

Thanks to the skills encompassed by this organisation, the CDMO can offer applied answers to genetic cloning, including the expression of coded proteins, their purification and characterisation and the issuance of the GMP of the Drug Substance. Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic non- human epidermal growth factor receptor HER2 -amplified BC.

The release technologies studied in this field are also applied to the treatment of dermatological pathologies the ongoing projects concern the controlled release of proteins for the treatment of wounds and the protection of topical formulations containing active ingredients that, following exposure to sunlight, generate toxic species.

In this respect, over the last ten years, the Biotech Formulation unit has managed to develop partnerships in the public and private domains, becoming a point of reference for transverse research projects. It is proposed that these integrated platforms will concentrate, above all, on developing new drugs for pathologies that still do not have effective treatments.

Cenegermin August 23, 9: Therefore these two amino acid changes have no influence on the final active ingredient rhNGFwhich is identical to the naturally secreted human protein. This site uses third party cookies. You are going to leave this site. Do you want to be redirected to the mobile version? An endeavour that starts out thanks to the research of Nobel Prize winner Rita Levi Montalcini, for the development and production of potential biotechnological drugs for the treatment of rare eye diseases.


The loss of corneal sensation impairs corneal health causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and perforation in severe cases. This study is aimed at assessing the safety and the efficacy of two dose regimens of recombinant human nerve growth factor rhNGF eye drops solution compared to vehicle for inducing a complete healing of stage 2 persistent epithelial defect and 3 corneal ulcer neurotrophic keratitis.

By continuing to use this web site, you are consenting to the use of cookies. In the first part of the downstream process, the inclusion bodies, coming from the upstream phase, are solubilised and then the folding phase starts.

To achieve the ambitious goal of providing answers to health questions, the continual pursuit of excellence and the ability to work as a system are, in fact, critical. The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after organ transplantion.

By continuing to use this web site, you are consenting to the use of cookies. The product was granted additional orphan drug designation for the treatment of neurotrophic keratitis in the U. The intervention concerned the creation of new areasconsisting of a four-storey building dedicated to the production process of coated granules, a three-storey building for packaging and a new warehouse.

Cenegermin contains amino acids and has a relative molecular mass of 13, Daltons and the following molecular formula: For information, including how to block the cookies, click here. We suggest you to update it for free by following one of the these links, choosing the browser you prefer: An audit trail system serves to register, in an inalterable manner, every operation carried out during processing.

Career Paths

It acts as an inhibitor of IL-8, a molecule involved in the inflammatory processes leading to the progressive autoimmune destruction of the cells of the islets of Langerhans in type 1 diabetes. Every production activity takes origin with the beginning of the upstream phase. Reparixin is the first of a new class of low-molecular-weight inhibitors that is selectively capable of modulating the activity of the receptor through an allosteric mechanism of action.


Food and Drug Administration today approved the first drug, Oxervate cenegerminfor the treatment of neurotrophic keratitis, a rare disease affecting the cornea the clear layer that covers the colored portion of the front of the eye. Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation.

DOMPE « New Drug Approvals

We suggest you to update it for free by following one of the these links, choosing the browser you prefer: Click here to learn more. At its biotech plant, the company has specialised in the development of new processes and in the production of biotech products on an industrial scale. Regarded as among the world’s foremost experts on corneal diseases, he was appointed Adjunct Assistant Professor of Biology at Temple University of Philadelphia.

Dpmpe packaging — in a controlled air environment — in which the pharmaceutical product is inserted into the individual stick, packet or container. The collaborations in the territory have the objective of creating new knowledge and developing suitable expertise for the profound technological and innovative transformation that is revolutionizing the health sector worldwide.

L’Aquila hub

The bacteria, coming from the cell bank, are inoculated inside fermenters that contain culture medium devised to facilitate bacterial growth. The protein—in this case Nerve Growth Factor, NGF —is produced using a living organism the bacterium Escherichia Coli of which the entire genome and the complex of biological interactions is known in detail. Medical Affairs xompe the medical-scientific benchmark of excellence when it comes to the production and disclosure of clinical data.

The site covers an area ofsquare metres. Several laboratories are up and running at CDMO, for analytical development and quality control, making it possible to conduct the most in-depth analyses in the biotechnology field. Cenegermin is a human beta-nerve growth factor beta-ngf – – peptide non-covalent dimer produced in escherichia coli. This site uses third party cookies. By continuing to use this web site, you are consenting to the use of cookies.

You are going domppe leave this site.